# Tofacitinib in Patients Hospitalized With Moderate and Severe COVID-19: Not Just Another Kinase Inhibitor

## TL;DR

This study found that adding tofacitinib to standard care did not improve survival or reduce hospital stays for severe COVID-19 patients.

## Contribution

The study evaluates tofacitinib's effectiveness in severe COVID-19, showing no mortality benefit and longer hospital stays.

## Key findings

- No significant difference in mortality between tofacitinib and standard care groups.
- Patients receiving tofacitinib had significantly longer hospital stays.

## Abstract

Background

There has been an intense search for pharmacological agents that can complement corticosteroid therapy in the treatment of severe coronavirus disease 2019 (COVID-19). The Janus kinase inhibitor tofacitinib has shown promise in this regard. This study aimed to determine the impact of adding tofacitinib to standard care on the mortality and total duration of hospital stay in severe COVID-19.

Methodology

This retrospective study compared the mortality and total duration of hospital stay among patients admitted with severe COVID-19 to a designated COVID-19 hospital in south India who had received tofacitinib in addition to standard care versus standard care alone. Medical case records of severe COVID-19 patients were retrieved and screened for inclusion. Categorical variables such as mortality were expressed as proportions and compared using the chi-square test, while continuous variables such as total duration of hospital stay were compared via the independent t-test. The odds ratio (OR) was calculated for the mortality difference between the two groups. P-values ≤0.05 were considered significant.

Results

Following the initial screening of 250 medical records, 186 patients were included in the final analysis, of whom 103 had received tofacitinib and 83 had received standard care. There was no significant difference in mortality between the two groups (OR = 1.58 (95% confidence interval = 0.71 to 3.51); p = 0.26). The total duration of hospital stay was significantly longer among those in the tofacitinib group (17.14 ± 8.85 days vs. 14.04 ± 5.48 days; p = 0.01).

Conclusions

Tofacitinib did not improve the clinical outcomes when used to supplement corticosteroids in the treatment of severe COVID-19.